Alexis, Andrew F., Joseph F. Merola, Yichen Zhong, Joe Zhuo, Brandon Becker, Andrew Napoli, Jessie Ross, Jennifer Beaumont, Michael DeRosa, Subhashis Banerjee, and April W. Armstrong. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch As Assessed by the Psoriasis Symptoms and Signs Diary”. SKIN The Journal of Cutaneous Medicine 8, no. 2 (March 18, 2024): s358. Accessed September 20, 2024. https://dermsquared.com/skin/article/view/2653.